ARCA BIOPHARMA ANNOUNCES STEERING COMMITTEE OF LEADING INTERNATIONAL CARDIOLOGY AND ELECTROPHYSIOLOGY EXPERTS FOR PRECISION-AF PHASE 3 CLINICAL TRIAL Posted on April 23, 2019 by ARCA IT - Press Release, Uncategorized PRECISION-AF Steering Committee - FINAL
IDENTIFICATION OF PHOSPHODIESTEREASE 3A POLYMORPHISM WITH POTENTIAL TO INCREASE EFFECTIVENESS OF PDE3 INHIBITORS PUBLISHED IN THE JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Posted on March 18, 2019 by ARCA IT - Press Release, Uncategorized PDE3A PMx JACC - FINAL
DOSE RESPONSE OF BETA-BLOCKERS IN ADRENERGIC RECEPTOR POLYMORPHISM GENOTYPES PAPER PUBLISHED IN CIRCULATION: GENOMIC AND PRECISION MEDICINE Posted on March 6, 2019 by ARCA IT - Press Release, Uncategorized Beta Blocker Dose Response in AR Polymorphism Genotypes - Circ Genom Precis Med - FINAL
ARCA BIOPHARMA ANNOUNCES FISCAL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Posted on February 27, 2019 by ARCA IT - Press Release, Uncategorized ABIO - YE18 Financial Results and Business Update - FINAL
ARCA BIOPHARMA ANNOUNCES FDA AGREEMENT FOR A SINGLE PHASE 3 CLINICAL TRIAL TO SUPPORT APPROVAL FOR THE FIRST GENETICALLY-TARGETED CARDIOVASCULAR DRUG Posted on February 20, 2019 by ARCA IT - Press Release, Uncategorized Gencaro Phase 3 FDA SPA Agreement - FINAL
ARCA BIOPHARMA UPDATES SPECIAL PROTOCOL ASSESSMENT REQUEST TO FDA FOR GENCARO PHASE 3 ATRIAL FIBRILLATION CLINICAL TRIAL Posted on December 20, 2018 by ARCA IT - Press Release, Uncategorized Gencaro Phase 3 FDA SPA Amendment- FINAL
ARCA BIOPHARMA ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Posted on November 14, 2018 by ARCA IT - Press Release, Uncategorized ABIO - 3Q18 Financial Results and Business Update - FINAL
GENETIC-AF PHASE 2B CLINICAL TRIAL ATRIAL FIBRILLATION BURDEN (AFB) RESULTS PRESENTED AT AMERICAN HEART ASSOCIATION 2018 SCIENTIFIC SESSIONS Posted on November 12, 2018 by ARCA IT - Press Release, Uncategorized AHA 2018 - GENETIC-AF AFB Poster Presentation - FINAL
GENETIC-AF Atrial Fibrillation Burden Results – AHA 2018 Posted on November 11, 2018 by ARCA IT - Uncategorized GAF AFB poster for AHA 11118
ARCA BIOPHARMA ANNOUNCES PHASE 2B GENETIC-AF ATRIAL FIBRILLATION BURDEN (AFB) RESULTS SELECTED FOR PRESENTATION AT AMERICAN HEART ASSOCIATION 2018 SCIENTIFIC SESSIONS Posted on November 5, 2018 by ARCA IT - Press Release, Uncategorized AHA 2018 - GENETIC-AF AFB Poster Presentation Announcement - FINAL